Completed PHASE2 INTERVENTIONAL NCT00312364

Safety and Efficacy Study of MRE0094 to Treat Chronic, Neuropathic, Diabetic Foot Ulcers

Sponsor: Pfizer

Conditions Diabetes Complications Foot Ulcer, Diabetic

Interventions MRE0094

Updated 7 times since 2017 Last updated: May 24, 2012 Started: Dec 31, 2005 Primary completion: Dec 31, 2007 Completion: Dec 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Diabetes Complications and Foot Ulcer, Diabetic, this trial is completed. The trial is conducted by Pfizer and has accumulated 7 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Altoona, United States , Ann Arbor, United States , Austintown, United States , Bakersfield, United States , Baton Rouge, United States , Bismarck, United States , Boise, United States , Bountiful, United States , Bullhead City, United States and 49 more locations